Eastmoney Fund CSI SH-HK-SZ Brand Name Drug Industry ETF

CSPC PHARMA FY2026 Q1 Earnings Release on May 27 Pre-Market (BJT), Forecast Revenue HKD 7.905 B, EPS HKD 0.102

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

512010

589720

159286

560900

159622

520970

159835

515120

516060

New State Council policies explicitly establish a 'price protection period' for innovative drugs, allowing high-level innovative drugs to set their own prices during the initial launch phase and enjoy this protection period. Centralized procurement will not touch innovative drugs, while a diversified commercial insurance payment system simultaneously opens up new space. Stimulated by this news, the A-share innovative drug sector surged strongly in the afternoon session, with multiple stocks hitting the limit up. Brokerage firms point out that the convergence of earnings realization, valuation repair, and policy catalysts may have ushered in a new wave of market activity for the innovative drug sector

Wallstreetcn

E Fund CSI 300 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Penghua CNI HK Connect Innovative Drugs ETF

ChinaAMC CSI Biotechnology Theme ETF

J.P.Morgan Asset Management CSI Brand Name Drug Industry ETF

E Fund CSI Innovative Drugs ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

Harvest CSI Hong Kong Connect Innovative Drugs ETF

Yinhua CSI Innovative Drugs Industry ETF

CCB Principal CSI Innovative Drugs Industry ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

GF CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern CSI Brand Name Drug Industry ETF

ICBCCS CSI Brand Name Drug Industry ETF

PKU HEALTHCARE

SL PHARM

HPGC

HISUN

Hvsen Biotech

YKYY

Staidson BioPharm

Hengrui Pharma

HENGRUI PHARMA

BeOne Medicines

BEONE MEDICINES

InnoCare Pharma

INNOCARE

RemeGen

REMEGEN

Shenwan Hongyuan

SWHY

SHCF

Beigene

SWHYHK

Explosive Growth in Innovative Drugs: Top-Level Pricing Mechanism Reform, Who Will Be the Biggest Winner?

800医药

510660

In the first quarter of 2026, China's innovative drug industry performed exceptionally well, with the total amount of out-licensing transactions exceeding USD 60 billion, nearly half of the total for the entire year of 2025. The National Medical Products Administration approved 13 innovative drugs for market launch, of which 6 are first-in-class drugs, covering key disease areas. The total number of innovative drugs under research in China reached 4,751, accounting for 33.7% of the global total, with over 45% in several cutting-edge fields. China has become the world's largest country for innovative drugs under research, with transaction volume accounting for 49% of the global total

腾讯新闻 - 财经

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

Yinhua CNI HK Connect Innovative Drugs ETF

JPMorgan Chase

INNOVENT BIO

Eli Lilly

CSPC PHARMA

AstraZeneca

CITIC Securities Co., Ltd.

CITIC SEC

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

AstraZeneca PLC

Mindset Observation Institute: In the first quarter, China's innovative drugs delivered an exciting report card

The General Office of the State Council issued "Several Opinions on Improving the Price Formation Mechanism for Pharmaceuticals," establishing a pricing governance logic for drugs centered on clinical value and innovation level. Experts indicate that this policy provides stable expectations and autonomous pricing space for the innovative drug industry, promoting industry profitability. In the first quarter, the total amount of external licensing transactions for innovative drugs exceeded USD 60 billion, and the innovative drug sectors in both the A-share and Hong Kong markets rebounded strongly. Despite the favorable policy, the contradictions between medical insurance payments and hospital usage still need to be resolved

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

Ping An CSI HK Equities Medical and Health Integration ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

CICC

From "Medical Insurance Negotiation Price Reduction" to "Self-Determined Pricing Protection": The drug price formation mechanism directly addresses the biggest pain point, and innovative drugs welcome a return to value

161122

The CSI Innovative Drugs Industry Index surged 11% over the past week. Brokerages believe the innovative drug sector is in a stage of "earnings realization, valuation repair, and conference catalysis." Multiple biopharmaceutical companies have achieved historic turnarounds, with fundamentals improving. In the first quarter of this year, the total amount of China's innovative drug out-licensing reached nearly $57 billion, already exceeding the full-year level of 2024. The upcoming AACR and ASCO annual meetings, with intensive clinical data disclosures, are expected to provide catalysts

E Fund CSI WD Biotechnology Index Fund(LOF)-A

Wanjia CSI Hong Kong Connect Innovative Drugs ETF

Invesco Great Wall CSI Hong Kong Connect Innovative Drug ETF

Innovative Drugs Break Out Again After Six Months, Leading Companies Enter Intensive Harvest Period; Has the Profit Inflection Point Arrived?

520880

159883

588130

159506

516930

A New Era for Chinese Innovative Drugs: Transitioning from "Pipeline Narrative Driven" to "Profit Value Realization"

华尔街见闻资讯

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Minsheng Royal CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC CSI All Share Health Care Devices ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

A New Era for Chinese Innovative Drugs: Transitioning from "Pipeline Narrative Driven" to "Profit Value Realization"

159102

520500

In 2026, the business expansion transactions of China's innovative drugs continued to heat up, with 44 external licensing transactions occurring within the year, totaling over USD 53 billion, with an upfront payment of approximately USD 3.123 billion

Huaan Hang Seng Biotech ETF

China Universal CNI BIOMEDICINE ETF

China Universal Hang Seng Biotechnology Technology ETF(QDII)

Huatai-PB CSI Hugangshen Innovative Drugs Industry ETF

Fullgoal Hang Seng Biotech ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Huatai-PB Hang Seng Biotech ETF

Guotai Hang Seng Biotech ETF

Chinese innovative drugs are making strong strides overseas, with total overseas licensing amounts exceeding 53 billion USD this year

002422

06990

01093

Mainland Chinese investors have increased their investments in Hong Kong-listed drug stocks, with the Hang Seng Southbound Connect Hong Kong Innovative Drug Index rising about 9% recently. CSPC Pharmaceutical Group and Sichuan Kelun-Biotech saw significant gains. Innovent Biologics announced a major collaboration with Eli Lilly worth up to $8.85 billion, enhancing its drug development process. This trend reflects a shift in how Chinese drug makers engage with global partners, as they gain more control over the development of their medicines amid a competitive pharmaceutical landscape.

Eastmoney Fund CSI SH-HK-SZ Brand Name Drug Industry ETF(159622.SZ)

Explosive Growth in Innovative Drugs: Top-Level Pricing Mechanism Reform, Who Will Be the Biggest Winner?

Mindset Observation Institute: In the first quarter, China's innovative drugs delivered an exciting report card

From "Medical Insurance Negotiation Price Reduction" to "Self-Determined Pricing Protection": The drug price formation mechanism directly addresses the biggest pain point, and innovative drugs welcome a return to value

Innovative Drugs Break Out Again After Six Months, Leading Companies Enter Intensive Harvest Period; Has the Profit Inflection Point Arrived?

A New Era for Chinese Innovative Drugs: Transitioning from "Pipeline Narrative Driven" to "Profit Value Realization"